CN114569552A - 抗疟疾组合物及其用途 - Google Patents

抗疟疾组合物及其用途 Download PDF

Info

Publication number
CN114569552A
CN114569552A CN202111196136.0A CN202111196136A CN114569552A CN 114569552 A CN114569552 A CN 114569552A CN 202111196136 A CN202111196136 A CN 202111196136A CN 114569552 A CN114569552 A CN 114569552A
Authority
CN
China
Prior art keywords
formula
compounds
crystalline
alkyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111196136.0A
Other languages
English (en)
Chinese (zh)
Inventor
维尔·约瑟夫·安达哈叙
阿纳布·K·查特吉
卡斯·W·麦克纳马拉
费德里科·C·比斯利
安德斯·米卡尔·伊莱亚森
汉克·迈克尔·詹姆斯·佩特拉希
詹森·T·罗兰
蒂莫西·威尔斯
奥尔加·弗拉基米罗芙娜·萨托洛赫纳亚
周飞
彼得·G·舒尔茨
阿尼尔·库马尔·古普塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of CN114569552A publication Critical patent/CN114569552A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/32—Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62—Halogen-containing esters
    • C07C69/65—Halogen-containing esters of unsaturated acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202111196136.0A 2016-06-20 2017-06-19 抗疟疾组合物及其用途 Pending CN114569552A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662352455P 2016-06-20 2016-06-20
US62/352,455 2016-06-20
CN201780050449.0A CN109715147A (zh) 2016-06-20 2017-06-19 抗疟疾组合物及其用途
PCT/US2017/038173 WO2017222996A1 (en) 2016-06-20 2017-06-19 Antimalarial compositions and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780050449.0A Division CN109715147A (zh) 2016-06-20 2017-06-19 抗疟疾组合物及其用途

Publications (1)

Publication Number Publication Date
CN114569552A true CN114569552A (zh) 2022-06-03

Family

ID=60784061

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111196136.0A Pending CN114569552A (zh) 2016-06-20 2017-06-19 抗疟疾组合物及其用途
CN201780050449.0A Pending CN109715147A (zh) 2016-06-20 2017-06-19 抗疟疾组合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780050449.0A Pending CN109715147A (zh) 2016-06-20 2017-06-19 抗疟疾组合物及其用途

Country Status (12)

Country Link
US (3) US10947176B2 (enExample)
EP (1) EP3471711A4 (enExample)
JP (1) JP2019523779A (enExample)
KR (1) KR20190020774A (enExample)
CN (2) CN114569552A (enExample)
AU (1) AU2017281426B2 (enExample)
BR (1) BR112018076619A2 (enExample)
CA (1) CA3028392A1 (enExample)
EA (1) EA201990064A1 (enExample)
MA (1) MA45411A (enExample)
SG (2) SG10202112759SA (enExample)
WO (1) WO2017222996A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10947176B2 (en) * 2016-06-20 2021-03-16 The Scripps Research Institute Antimalarial compositions and uses thereof
US12520840B2 (en) * 2018-09-04 2026-01-13 President And Fellows Of Harvard College Method for reducing parasite burden in a mosquito
EP4149510A4 (en) 2020-05-11 2024-05-22 Oregon Health & Science University Novel intermediates and synthesis for endochin-like quinolone compounds
WO2022144920A1 (en) * 2020-12-30 2022-07-07 Ipca Laboratories Limited Atovaquone prodrugs
WO2025151263A1 (en) * 2024-01-09 2025-07-17 Sri International Oil-based compositions and methods of making and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580185A1 (en) * 1988-08-16 1994-01-26 The Wellcome Foundation Limited Medicaments

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206268A (en) * 1988-08-16 1993-04-27 Burroughs Wellcome Co. Medicaments
GB8819477D0 (en) * 1988-08-16 1988-09-21 Wellcome Found Medicaments
US5021426A (en) * 1990-02-26 1991-06-04 Merck & Co., Inc. Method of traeting malaria with cyproheptadine derivatives
GB9207517D0 (en) 1992-04-06 1992-05-20 Wellcome Found Heterocyclic compounds
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
ITMI20070941A1 (it) * 2007-05-09 2008-11-10 Chimico Internazi0Nale S P A L Procedimento per la preparazione di naftochinoni trans2,3-disostituiti
US10947176B2 (en) * 2016-06-20 2021-03-16 The Scripps Research Institute Antimalarial compositions and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580185A1 (en) * 1988-08-16 1994-01-26 The Wellcome Foundation Limited Medicaments

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SALOME´ EL HAGE等: "Synthesis and antimalarial activity of new atovaquone derivatives", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 *
曹丹: "纳米混悬剂的研究新进展", 《科技信息》 *

Also Published As

Publication number Publication date
CA3028392A1 (en) 2017-12-28
BR112018076619A2 (pt) 2019-04-02
EA201990064A1 (ru) 2019-05-31
US10947176B2 (en) 2021-03-16
US20210179524A1 (en) 2021-06-17
KR20190020774A (ko) 2019-03-04
SG11201811434RA (en) 2019-01-30
US20190202766A1 (en) 2019-07-04
WO2017222996A1 (en) 2017-12-28
MA45411A (fr) 2019-04-24
AU2017281426A1 (en) 2019-01-17
AU2017281426B2 (en) 2021-10-14
CN109715147A (zh) 2019-05-03
SG10202112759SA (en) 2021-12-30
US11485697B2 (en) 2022-11-01
EP3471711A1 (en) 2019-04-24
EP3471711A4 (en) 2020-02-19
JP2019523779A (ja) 2019-08-29
US20230111793A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
CN114569552A (zh) 抗疟疾组合物及其用途
CN103781783B (zh) 作为抗精神病药物的哌嗪取代的苯并噻吩衍生物
KR101290893B1 (ko) 피롤리디늄 염의 제조 방법
ES2371549T3 (es) Montelukast en estado sólido.
AU2017242867B2 (en) Vortioxetine pamoic acid salt and crystal form thereof
JPH07502742A (ja) Ｐａｆ−レセプタ拮抗剤としてのアミノ酸誘導体
AU2006271297B2 (en) Novel heterocyclidene acetamide derivative
CA2676020A1 (en) Heterocyclidene-n-(aryl) acetamide derivative
JP2010095550A (ja) キノリン誘導体
WO2025007074A9 (en) Chemical compounds
CA2683939C (en) Aspartate of 1-cyclopropyl-6-fluoro-7-(8-methoxyimino-2,6-diaza-spiro[3.4]oct-6-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid, method for preparing the same, and antimicrobial pharmaceutical composition comprising the same
RU2300532C2 (ru) Производные бензо[g]хинолина для лечения глаукомы и близорукости, способ их получения и фармацевтическая композиция
WO2023213182A1 (zh) 一种卡瑞斯汀的盐及其用途
JP2010037341A (ja) 医薬化合物
CN102532114A (zh) 烟酸衍生物,其制备方法及其药物组合物
US20240317774A1 (en) Pharmaceutical Compound
CN102395369A (zh) 含有四氢吡啶[4，3-b]吲哚衍生物的缓释组合物及该衍生物的制备方法
AU2022395361A1 (en) Pyrazine compounds useful in the treatment of parasitic protozoal infection
OA19130A (en) Antimalarial compositions and uses thereof
Barteselli SYNTHESIS OF NEW POLYCYCLIC COMPOUNDS WITH POTENTIAL ANTIMALARIAL AND/OR ANTILEISHMANIAL ACTIVITY

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220603